The pro-drug mycophenolate mofetil is an immunosuppressive agent widely used for the prevention or treatment of acute rejection after solid organ transplantation. Mycophenolate mofetil is given orally, absorbed and converted to mycophenolic acid, the active immunosuppressant form. Mycophenolic acid acts by inhibition of type II inosine monophosphate dehydrogenase (IMPDH II), a key enzyme in the de novo purine biosynthetic pathway. Mycophenolic acid is mainly metabolized by glucuronidation to its inactive hydroxy-β-glucuronide (MPAG) (Bullingham et al., 1998) . MPAG is partly excreted into the bile and contributes to mycophenolic acid enterohepatic circulation after deglucuronidation in the gut (Bullingham et al., 1998) . In addition, two other metabolites, i.e. MPA-acylglucuronide (AcMPAG) and MPA-phenyl-glucoside (MPAGls), were isolated in renal transplants' plasma and identified by tandem mass spectrometry (Schutz et al. 1999; Shipkova et al., 1999) . A recent report demonstrated that AcMPAG had an inhibitory effect on lymphocyte proliferation in vitro (Shipkova et al., 2001b) . On the other hand, the toxicity of acyl-glucuronides is well known (Ritter, 2000; Shipkova et al. 2003) : they can bind covalently to proteins and other macromolecules, which is thought to be the mechanism of their immunogenicity and toxicity. AcMPAG might thus be responsible for some of the adverse effects of mycophenolate mofetil therapy, such as leucopenia or gastro-intestinal toxicity . MPA glucosides (MPAGls) did not exhibit immunosuppressive activity (Schutz et al., 1999) and nothing is known about their toxicity.
Significant pharmacokinetic interactions between mycophenolate mofetil and other immunosuppressants have been described. Mycophenolic acid exposure is lower when cyclosporin is associated to mycophenolate mofetil which would be due to inhibition of the enterohepatic cycling of mycophenolic acid, though this needs further evidence (Smak Greggoor et al., 1999) . Mycophenolic acid in vivo concentrations and in vitro immunosuppressant activity seem to be higher when mycophenolate mofetil is administered This article has not been copyedited and formatted. The final version may differ from this version. with tacrolimus than with cyclosporin, with a corresponding reduction of MPAG concentrations (Hübner et al., 1999; Zucker et al., 1997) . This suggests an inhibition of mycophenolic acid metabolism by tacrolimus, further demonstrated in vitro (Zucker et al., 1999) . Steroids also interfere with mycophenolic acid bioavailability, likely through induction of the UGT isoforms involved in MPAG formation, as described by Cattaneo et al. (2002) . No data regarding possible drug-drug interactions resulting in concentration variations of the active and presumably toxic AcMPAG are available. A better knowledge of the metabolic pathways of mycophenolic acid is necessary to better investigate such interactions.
To date, at least 15 forms of UDP-glucuronosyltransferases (UGT) have been identified in humans. Based on sequence similarities, they have been divided into two families, UGT 1 and UGT 2. The UGT isoforms involved in the glucuronidation of mycophenolic acid to MPAG were previously studied by several teams, but remain debated. Morissette et al. (2001) demonstrated that mycophenolic acid glucuronidation into MPAG is more intensive in men than in women suggesting that mycophenolic acid could compete with estrogens for the UGT 1A class. Shipkova et al. (2001) suggested that most of the UGT 1A and 2B were involved in MPA metabolism, with UGT 1A7 and 2B4 being the most active. For Mackenzie (2000) , UGT 1A8, 1A9 and 1A10 have the capacity to glucuronidate mycophenolic acid, while UGT 1A1, 1A3, 1A4, 1A6, 2B4, 2B7 and 2B10 are inactive (Mojarrabi and Mackenzie, 1997) . Basu et al. (2004) and Bernard and Guillemette (2004) also found that UGT 1A7, 1A8, 1A9, 1A10 were able to produce MPAG, but there was substantial differences in the catalytic activities observed: for Bernard and Guillemette UGT 1A8 and 1A9 are the main isoforms producing MPAG and UGT 1A1, 1A7 and 1A10 have low capacities, whereas Basu et al. (2004) found catalytic activities as follows: UGT 1A7 > 1A9 > 1A8 > 1A10. Finally, it is worth noting that the UGT isoforms producing AcMPAG have only been studied by Basu et This article has not been copyedited and formatted. The final version may differ from this version. This study describes the full in vitro/in vivo characterization of the different phase II metabolites of mycophenolic acid, some of which have been identified by only one team so far , and the investigation of the UGT isoforms responsible for the formation of MPAG and above all AcMPAG using complementary in vitro models and a specific and sensitive LC-MS/MS method.
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Materials and methods

Chemicals and reagents.
Mycophenolic acid, indomethacin, UDP-glucose, UDP-glucuronic acid, type 2 β-glucuronidase from Helix Pomatia (EC 3.2.1.31), β-glucosidase from almonds (EC 3.2.1.21), triton X-100, 3-methylcholanthrene, phenobarbital and propofol were obtained from SigmaAldrich (St-Louis, MO, USA), azidothymidine from Glaxo SmithKline (Nanterre, France), MgCl 2 from Merck (Darmstadt, Deutschland) and MPAG from Analytical Services International Ltd (London, England). All reagents were analytical grade.
In vivo investigation of mycophenolic acid metabolites
Mycophenolic acid metabolites were investigated in urine and plasma samples collected in renal transplant recipients (n=14) grafted for more than 30 days who had given their informed consent to participate in a pharmacokinetic study of cyclosporin and mycophenolate mofetil.
All patients received 1 g mycophenolate mofetil twice daily and a dose of cyclosporin adjusted to yield a trough level of 150-200 ng/mL. Urine and plasma samples were acidified with 10 µl/ml of phosphoric acid in order to prevent AcMPAG degradation then stored at -20 °C until analysis. The inter-dose area under the concentration-time curve (AUC 0-12h ) of mycophenolic acid, AcMPAG, MPAG and MPAGls were calculated using the linear trapezoidal rule and the average metabolic ratio of each metabolite was calculated in each patient.
In vitro metabolic experiments
Human microsomes
Pooled human liver microsomes were obtained from BD Biosciences/GENTEST (Woburn, MA, USA). Pooled human kidney and intestinal microsomes were prepared as previously described (Picard et al., in press ) from normal kidney (n=4) and ileal (n=4) tissues adjoining tumor tissues from surgical specimens, with the approval of the local ethics committee. Protein concentration of the microsomal suspension was measured according to the Bradford's method using bovine serum albumin as standard.
Rat liver microsomes
Male Sprague-Dawley rats were treated with phenobarbital sodium and 3-methylcholanthrene. Phenobarbital, dissolved in 0.9% NaCl, was administered i.p. at a dose of 70 mg/kg once daily for 3 days; 10 mg/kg/day of 3-methylcholanthrene, in solution in corn oil, were injected i.p. for 3 days. NaCl without phenobarbital or corn oil without 3-methylcholanthrene were administered following the same protocol to control rats. The rats were then killed by decapitation and liver removed. Rat liver microsomes were obtained by differential centrifugations as previously described (Picard et al., in press ).
Recombinant UGT
Microsomes prepared from baculovirus-infected insect cells that expressed the human UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7 (Supersomes ® ) as well as a control preparation were obtained from BD Biosciences/GENTEST (Woburn, MA, USA).
The glucuronidation activity of each UGT Supersomes ® were substantiated by the supplier for the following substrates: estradiol (UGT 1A1 and 1A3), trifloperazine (UGT 1A4) and 7-hydroxy-4-trifluoromethylcoumarin (UGT 1A6, 1A7, 1A8, 1A9, 1A10, 2B4 and 2B7).
Incubations procedures
The typical incubation mixture (500 µl) contained 0.5 mg/ml microsomal proteins (HLM, HKM, HIM, rat liver microsomes or Supersomes 
Chemical inhibition experiments
The individual contribution of UGT 1A9 and 2B7 in MPAG or AcMPAG production was evaluated in HLM, HKM and HIM using propofol (Ebner and Burchell, 1993) and azidothymidine (Barbier et al., 2000; Court et al., 2003) as selective substrates, respectively.
The inhibitors were tested at 4 increasing concentrations (50 -500 µM) to assess the maximal selective inhibition. The same incubation procedure as described above was followed, except that inhibitors were added to the incubation medium before starting the reaction. Inhibitors were dissolved in DMSO and control incubations were spiked with the same amount of DMSO (≤ 1% v/v). MPAG or AcMPAG formation rates in the presence of the inhibitors were compared with those of the corresponding controls and the percentage of inhibition calculated.
Hydrolysis experiments
To confirm the position of the glucuronide and glucoside moieties on MPA, the effect of alkaline or enzymatic hydrolysis on metabolites produced in vitro was tested.
Reaction mixtures (1 ml) containing the target glucuronides or glucosides were generated by incubating 0.5 mM mycophenolic acid and 0.5 mg/ml microsomes as described above. hours at room temperature. The concentration of conjugates was determined using LC-MS/MS and the hydrolysis rate calculated.
LC-MS/MS analysis
Identification of mycophenolic acid metabolites
Identification experiments were performed after solid-phase extraction. 500 µl incubation medium samples diluted 1/3 with water were passed through a 60 mg Oasis MAX extraction cartridge (Waters, Milford, Mass, USA) previously activated with 2 ml methanol followed by 2 ml H 2 O. The cartridge was rinsed with 2 ml of 50 mM, pH=7 sodium acetate / methanol (95/5; v/v) and elution was achieved with 1 ml methanol containing 2 % formic acid. The extract was evaporated to dryness and reconstituted in 50 µl acetonitrile / ammonium formate experiments were used to investigate the fragmentation pathways and metabolite structure.
Determination of mycophenolic acid and metabolites
Mycophenolic acid and MPAG in renal transplants were determined using a previously described, fully validated LC-MS/MS method (Prémaud et al., in press ). AcMPAG, MPAGls and AcMPAGls were determined using the same method with minor modifications: specific were analyzed with each run. AcMPAG, AcMPAGls and MPAGls concentrations were estimated as MPAG molar equivalents with respect to MPAG calibration curves because of the lack of the respective pure compounds. The minor AcMPAGls was determined in vitro but not in renal transplants due to very low concentrations. The LOQ of the assay was 10 ng/ml for MPAG. Linearity was verified up to 1500 ng/ml (r=0.999). The between-day precision CVs and mean relative errors were less than 10% over the linearity range.
Kinetic modeling
All in vitro data points represent the mean of duplicate determination.
Microsomal kinetic data were model-fitted and apparent K m and V max calculated according to the Michaelis-Menten model using Winreg 3.1 software (available online 1 ).
Results
In addition to MPAG, three potential metabolites of mycophenolic acid were detected in urine samples using the precursor ion scan mode where compounds producing experiments which confirmed that MPAG (RT=10.0 min) and the supposed MPAGls (RT= 8.6 min) were stable to alkaline hydrolysis and subject to complete degradation by β-glucuronidase and β-glucosidase, respectively, whereas AcMPAG (RT= 13.6 min) and the supposed AcMPAGls (RT= 9.4 min) were degraded under alkaline conditions and stable to enzymatic hydrolysis (Table 4) , as previously reported for AcMPAG ).
Additionally, purified fractions corresponding to the metabolites' retention times (MPAG, AcMPAG and MPAGls) were obtained by a modification of the LC-MS/MS method to a preparative mode, then assayed using NMR (data not shown). The structure of MPAG was confirmed, but the signal/noise ratio was insufficient to confirm the putative AcMPAG and
MPAGls.
This article has not been copyedited and formatted. The final version may differ from this version. In renal transplants, the average MPAG AUC 0-12h was 11.2 to 37.2 times higher (average 24.1 times) than mycophenolic acid average AUC 0-12h . Apparent AcMPAG AUC 0-12h represented 2.9 to 11.8 % (mean = 6.2 %) of mycophenolic acid AUC 0-12h . Apparent MPAGls AUC 0-12h ranged from 1.7 to 11.1 % (mean = 5.4%) of mycophenolic acid AUC 0-12h .
In vitro metabolism of mycophenolic acid
When mycophenolic acid was incubated with HLM, HKM or HIM in the presence of UDPglucuronic acid, the two glucuronides previously identified (MPAG and AcMPAG) were produced, as confirmed by retention time and MS/MS spectra. Similarly, incubation with UDP-glucose led to the formation of the two glucosides identified in biological fluids. The microsomal kinetic parameters of MPAG, AcMPAG, MPAGls formation were calculated for HLM, HKM and HIM (Table 1) . Those of AcMPAGls were calculated for HLM and HKM but not for HIM because of a low activity. The maximal formation rate (V max ) of MPAG was about 2.5 times and K m 3 times higher for kidney than for liver, resulting in mycophenolic acid intrinsic clearance (CL int : V max /K m ratio) almost similar with both types of microsomes.
The apparent K m for AcMPAG formation was similar for kidney and liver, while V max was 3 times higher for liver, leading to CL int 3 times as much for liver than kidney microsomes.
According to CL int values, mycophenolic acid-phenyl-glucosylation was the second main elimination pathway for mycophenolic acid. HLM or HKM produced MPAGls with the same efficiency, while HLM was more efficient than HKM for AcMPAGls ?? production with much greater affinity. HIM showed the lowest activity of the three microsomal preparations for all the metabolites produced (Table 1) .
Mycophenolic acid glucuronidation by induced rat liver microsomes
Rat liver microsomes incubated with mycophenolic acid in the presence of UDP-glucuronic acid produced two glucuronides with the same retention times and MS/MS spectra as MPAG and AcMPAG, respectively. With microsomes obtained from 3-methylcholanthrene preThis article has not been copyedited and formatted. The final version may differ from this version. treated rat liver, MPAG formation was enhanced by 1.9 fold whereas there was no effect on AcMPAG production. The pre-treatment of rats with phenobarbital enhanced AcMPAG (1.5 fold) but not MPAG synthesis (Table 2) .
Mycophenolic acid glucuronidation by human recombinant UGT
Among the 10 UGT isoforms tested, UGT 1A9, 1A8, 1A7, 1A10 produced MPAG in significant amounts, with UGT 1A9 being the most active. UGT 1A1, 1A6, 2B7 and 2B4
showed little activity. AcMPAG production was mainly detected with UGT 2B7 and to a much lesser extent with UGT 1A1 and 2B4. No metabolite production was detected with UGT 1A3, 1A4 and control supersomes ® (Figure 3 ).
The kinetic parameters of MPAG and AcMPAG production were determined for the competent UGT isoforms (Table 3) , except UGT 2B4, 1A6 and 1A10, whose metabolite formation rate was so low that kinetic parameters could not be calculated. UGT 1A9 showed a Km of 0.16 mM for MPAG formation, close to the Km calculated for HLM (0.18 mM) and higher than UGT 1A7 and 1A8 affinity. UGT 2B7 was the isoform most efficiently producing AcMPAG.
Chemical inhibition of mycophenolic acid glucuronidation
The UGT 1A9 probe propofol decreased MPAG formation in a concentration dependent manner up to 47.0 % for HIM, 55.3 % for HLM and 76.3 % for HKM relatively to the respective controls. In contrast, there was no significant effect on AcMPAG formation by HLM, HKM or HIM. Inhibition of AcMPAG formation by the UGT 2B7 selective substrate azidothymidine was quite constant for all the concentrations tested with a maximum of 24.6 % for HLM and 26.1 % for HKM. In contrast, no inhibition was found for HIM.
Azidothymidine inhibition of MPAG production by HLM, HKM or HIM was less than 10 % (Figure 4 ). 
Discussion
The existence and nature of two glucuronides of mycophenolic acid, namely MPAG and AcMPAG, and two glucosides, as previously described by Shipkova et al. (1999) , were confirmed in vivo and in vitro using LC-MS/MS. Based on hydrolysis experiments, the second glucoside found in minor amount was identified as the acyl-glucoside of mycophenolic acid; this metabolite was previously observed in vitro, after incubation of mycophenolic acid with human renal microsomes, but not in vivo . The monitoring of specific ion transitions (MRM mode) allowed the specific and sensitive determination of these metabolites in vitro and in vivo.
Several clinical studies highlighted the fact that the kidney may contribute to mycophenolic acid metabolism based on comparison of urinary clearance of MPAG after oral or intravenous administration of mycophenolate mofetil and on the impact of hepatic impairment on MPAG clearance (Bullingham et al. 1996; Parker et al. 1996) . In vitro studies provided additional evidences: Zucker et al. (1999) reported that purified kidney extracts contained higher amounts of UGT involved in MPAG formation than liver extracts; comparison of kidney and liver microsomes for MPAG formation showed a higher activity of the former (Bowalgaha et al., 2001; Shipkova et al. 2001a, Bernard and Guillemette, 2004) . Accordingly, we confirmed that MPAG maximal formation rate (V max ) was 3 times higher for HKM than for HLM, with kinetic parameters quite similar to those previously reported (Vietri et al., 2000; Shipkova et al., 2001a; Bowalgaha et al 2001; Bernard and Guillemette, 2004) . Our results also suggest that AcMPAG is mainly produced by the liver, which is in accordance with the results of Shipkova et al. (2001a) . Mycophenolic acid glucosides seem to be produced by both liver and kidney but, contrary to Shipkova et al. who reported that the acyl-glucoside was produced by the kidney, the best affinity was observed here with liver microsomes, with 7.5 times higher Contradictory data on the UGT isoforms involved in MPAG production and their respective contribution were available and only one recent report studied the isoforms producing AcMPAG, using UGT transfected cell lines and TLC chromatography (Basu et al., 2004) . In the present study, experiments using induced rat liver microsomes clearly showed that different UGT isoforms were involved in MPAG and AcMPAG formation. Phenobarbital and 3-methylcholanthrene are two inducers of the cytochrome P450 and UGT isoforms.
Phenobarbital (inducer of the rat UGT 1A1 and 2B1) enhanced the formation of AcMPAG and it is worth noting that UGT 2B7 is described as the human orthologue of the rat UGT 2B1 (Ritter, 2000) , these two isoforms having many substrates in common. Moreover, the rat UGT 2B1 and the human UGT 2B7 appear to be major contributors to glucuronidation of carboxylic acid drugs to acyl-glucuronides (Ritter, 2000) . In contrast, MPAG formation was enhanced by 3-methylcholanthrene, which is a reported inducer of the rat and human hepatic UGT 1A6 (Grams et al., 2000) . The UGT isoforms involved in mycophenolic acid glucuronidation were further identified by incubation with recombinant enzymes (UGT Supersomes ® ). UGT 2B7 was confirmed to be responsible for production of AcMPAG, with higher activity in the liver. This UGT is expressed in liver, kidney and small bowel as demonstrated by immunoblot analysis and enzymatic assays (Czernik et al., 2000; Antonio et al., 2003; Fisher et al, 2001 ).When mycophenolic acid was co-incubated with the selective 2B7 substrate azidothymidine only a slight inhibition of AcMPAG production was observed with HLM and HKM and none with HIM. Thus, we cannot rule out that other, unexplored UGT isoforms could contribute to AcMPAG production. Nevertheless, this result could be UGT isoforms involved in MPAG formation have been previously studied using recombinant UGT cell lysates (Shipkova et al., 2001a ): all the isoforms tested were active, with UGT 1A7
and 2B4 being the most efficient. UGT 1A7 is only located in the small bowel and the use of a specific antibody directed against human UGT 2B4 demonstrated that this isoform was exclusively expressed in the liver (Pillot et al., 1993) . On the other hand, Mackenzie (2000) reported that the intestinal UGT 1A8 and 1A10 and the hepatic and renal UGT 1A9 were involved in MPAG formation using microsomes prepared from UGT transfected cells and thin layer chromatography. Finally, the recent reports of Basu et al. (2004) and Bernard and Guillemette (2004) described the UGT 1A7, 1A8, 1A9 and 1A10 as the major contributors to MPAG production. According to both incubation with human recombinant UGT isoforms and chemical inhibition experiments, the present report clearly shows that UGT 1A9 is the main isoform involved with at least 55 % contribution to the hepatic MPAG production. UGT 1A1
and 1A6 probably account for a part of MPAG hepatic production, while UGT 1A7, 1A8, 1A10 which are located in the small bowel could contribute to mycophenolic acid intestinal first pass effect. The recent works by Basu et al. (2004) using in situ hybridation of UGT1A9 mRNA showed that this isoform was also located in duodenal and ileal mucosa and thus could partly contribute to mycophenolic acid intestinal metabolism. Our results, based on chemical inhibition of UGT 1A9 by propofol, suggest that this isoform may be involved for approx. 40 % of MPAG intestinal production. Nevertheless, as previously reported (Shipkova et al., 2001a; Bowalgaha and Miners, 2001) , HIM showed much lower activity than kidney or liver microsomes, which is presumably due to a lower expression of UGT 1A9 in the intestine wall.
Although UGT 1A9 was originally described as a liver expressed UGT, the important contribution of the kidney to mycophenolic acid metabolism and the 75% decrease in MPAG production by kidney microsomes after selective UGT 1A9 inhibition, are consistent with This article has not been copyedited and formatted. The final version may differ from this version. many recent reports about its higher expression in the kidney: McGurk et al. (1998) found that the glucuronidation of propofol, a specific substrate of UGT 1A9, was higher in human kidney than liver. UGT 1A9 mRNA levels were also found to be higher in human kidney than liver (Albert et al, 1999) . Thus, the high kidney MPAG formation rate found in this study as well as in previous reports (Zucker et al., 1999; Shipkova et al., 2001a; Vietri et al., 2000; Bernard and Guillemette, 2004 ) is apparently mainly due to UGT 1A9.
Glucuronidation is an important feature of mycophenolic acid pharmacokinetics. Although the main metabolite MPAG is inactive, its AUC 0-12h is on average more than 20 times higher than that of mycophenolic acid. There is no doubt that this high metabolic rate contributes significantly to mycophenolic acid elimination and enterohepatic cycling. Thus glucuronidation could partly explain the high inter-individual variability of mycophenolic acid AUC 0-12h for a fixed 1g bid dose. The confirmation and (for AcMPAG) identification of the UGT isoforms involved in mycophenolic acid glucuronidation presented here will allow new investigations on mycophenolic acid pharmacogenetic-pharmacokinetic relationships, drug-drug interaction and adverse events. UGT 2B7, which is responsible for the production of the toxic acyl-glucuronide metabolite is muted in approx. 50 % of the Caucasian population, and this polymorphism could lead to a difference in metabolite production and thus in the hematological or digestive susceptibility to mycophenolic acid. 
